David Salzman

David is responsible for leading the scientific vision of the company which was founded based on his novel discovery of algorithms that identify mutations in small RNA genes, predict their regulatory targets, and designs corrective therapies for them.

David’s work spans over two decades, where he uncovered many of the functional roles small RNA play in biology, as well as seminal discoveries to the field regarding small RNA biogenesis and characterizing RISC activity.

Prior to Gatehouse Bio, David pioneered the creation of gold standard R&D tools that have been used in >50,000 publications, including the first two anti-DICER mAbs, and a dual-luciferase assay platform used to measure small RNA function. He has also held leadership roles in startups such as MiraDx, where he managed the development of commercial diagnostics for radiation and immunotherapy response and at Biogen where he designed and implemented the biomarker strategy to support the antisense oligo pipeline including BIIB067 (tofersen).

David is Business Advisor Board member for the Harvard Institute of RNA Medicine. David earned a PhD in molecular biology from the University of Connecticut and completed a postgraduate fellowship in radiation oncology and molecular genetics at the Yale University School of Medicine.